Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 3
1990 5
1991 4
1992 6
1993 1
1994 1
1995 1
1996 1
1997 3
1998 1
1999 1
2002 2
2003 2
2004 4
2005 1
2006 3
2007 5
2008 9
2009 16
2010 14
2011 12
2012 16
2013 14
2014 17
2015 22
2016 19
2017 6
2018 12
2019 11
2020 7
2021 18
2022 25
2023 22
2024 20
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Results by year

Filters applied: . Clear all
Page 1
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. Among authors: llibre jm. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Llibre JM, et al. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. Clin Infect Dis. 2023. PMID: 35235656 Free PMC article. Clinical Trial.
Redefining therapeutic success in HIV patients: an expert view.
Antela A, Rivero A, Llibre JM, Moreno S; RET Group. Antela A, et al. Among authors: llibre jm. J Antimicrob Chemother. 2021 Sep 15;76(10):2501-2518. doi: 10.1093/jac/dkab168. J Antimicrob Chemother. 2021. PMID: 34077524 Free PMC article. Review.
Prevention of Anal Cancer.
Revollo B, Videla S, Llibre JM. Revollo B, et al. Among authors: llibre jm. N Engl J Med. 2022 Aug 18;387(7):666. doi: 10.1056/NEJMc2209237. N Engl J Med. 2022. PMID: 36070726 No abstract available.
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands.
Bruguera A, Nomah D, Moreno-Fornés S, Díaz Y, Aceitón J, Reyes-Urueña J, Ambrosioni J, Llibre JM, Falcó V, Imaz A, Fanjul F, Navarro G, Pere D, León E, Mera A, Miró JM, Casabona J; PISCIS Cohort Group. Bruguera A, et al. Among authors: llibre jm. Int J Epidemiol. 2023 Aug 2;52(4):e241-e252. doi: 10.1093/ije/dyad083. Int J Epidemiol. 2023. PMID: 37403345 No abstract available.
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaró I, Borràs FH, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J; PICIS study group. Palacio-Vieira J, et al. Among authors: llibre jm. BMC Public Health. 2021 Aug 28;21(1):1596. doi: 10.1186/s12889-021-11613-y. BMC Public Health. 2021. PMID: 34454444 Free PMC article.
Genetic barrier to resistance for dolutegravir.
Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Llibre JM, et al. AIDS Rev. 2015 Jan-Mar;17(1):56-64. AIDS Rev. 2015. PMID: 25472016 Review.
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.
Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, Günthard HF, Zangerle R, Smith C, Castagna A, d'Arminio Monforte A, Wit F, Stecher M, Lehman C, Mussini C, Fontas E, González E, Wasmuth JC, Sönnerborg A, De Wit S, Chkhartishvili N, Stephan C, Petoumenos K, Jaschinski N, Vannappagari V, Gallant J, Young L, Volny Anne A, Greenberg L, Martín-Iguacel R, Poveda E, Llibre JM; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Álvarez H, et al. Among authors: llibre jm. Clin Infect Dis. 2023 Aug 22;77(4):593-605. doi: 10.1093/cid/ciad219. Clin Infect Dis. 2023. PMID: 37052343 Free PMC article.
283 results